Chemotherapy and Targeted Therapy for Endocri...

Drs. Zeina Nahleh and Maryam Lustberg join the podcast to discuss the updated ASCO guideline on breast cancer follow-up and surveillance after primary treatment. Drs. Nahleh and Lustberg explain the new risk-stratified approach, which personalizes surveillance intensity based on ...  Show more

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resist ...  Show more

This week’s episode  is part 2 of 2024 updates focusing on treatment options for localized breast cancer. We will discuss important details on radiation, as well as therapies based on ER/PR/her2 receptor status. We are honored to have Dr. Eleonora Teplinsky, a board-certified ...

<span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Drs. Hope Rugo and Sara Tolaney discuss the promise of antibody-drug conjugates (ADCs) in the treatment of breast cancer, highlighting key trials that shed light on matching the right ADC to the right p ...

Dr. Chino talks with Dr. Atif Khan and Dr. Lola Fayanju about the shift in breast cancer management from reducing locoregional recurrence and improving breast cancer mortality to deintensification, shared decision making, and improved quality of life. This discussion will be base ...  Show more

This 45-minute podcast features the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data wit ...